Linkingmed

Linkingmed develops and provides a cancer data analysis platform designed to assist medical institutions in analyzing oncology data. Its business model is centered on offering technical tools and cloud services to hospital radiotherapy departments and third-party imaging and radiotherapy centers on a B2B basis. The company generates revenue by selling its products and services, with an average price of around CNY 1.2 million, tailored to the traffic of the purchasing hospital. Its clients are primarily medical staff, including doctors, researchers, and physicists who use the platform to digitally review and issue cancer treatment plans.

The core of Linkingmed's offering is its suite of AI-powered radiotherapy cloud services, which includes tools for automatic organ contouring (AiContour), treatment auto-planning (AiPlan), and quality control (AiQA). A key feature is the ability to significantly reduce the time required for an oncologist to contour a tumor's target location from several hours to approximately 20 minutes, while also improving accuracy. The platform also facilitates remote collaboration, allowing specialists to serve patients in different locations. Its RAIC·OIS (Oncology Information System) and the AiContour system have received NMPA Class III medical device certification, marking their official commercialization. The company has raised a total of $15.3M in funding and has attracted investments from firms such as Grains Valley Venture Capital, Binhai Venture Capital, and Linear Capital Partners.